After claiming an FDA de novo nod in August, Abbott (NYSE: ABT) said it plans to launch its Libre Duo dual-analyte sensor in the U.S. this December. The roll out of the new continuous glucose monitor, which also tracks ketone levels to safeguard against diabetic ketoacidosis, will come after its international debut set for this […]
Wall Street Beat
Danaher’s Masimo acquisition offsets drops in respiratory diagnostic sales
Danaher (NYSE: DHR) posted earnings results from the first full quarter following its $9.9 billion acquisition of Masimo, which fueled a 16.5% boost in its diagnostics segment sales — but the contribution comes as declines in respiratory testing continue to drag the company’s core revenues. Still, the company largely met Wall Street’s expectations for the […]
Intuitive stock slides as US procedures slow amid $450M settlement
While Intuitive (NASDAQ: ISRG) posted strong revenue gains in its third-quarter earnings, it faced high expectations from Wall Street for procedure growth, which ultimately dragged its stock price down about 10% on the report. Quarterly revenue topped $3.05 billion, gaining 22% compared to 2025’s $2.51 billion and beating analysts’ estimates of $2.91 billion. That was […]
Abbott to spin out Nutrition business, cuts guidance
Abbott (NYSE: ABT) today reported mixed third-quarter results, cut its guidance and joined the trend of medtech conglomerates spinning out businesses to focus. ABT shares fell more than 2% to $99.50 apiece in morning trading. The S&P 500 was up slightly. The Abbott Park, Illinois–based Life Sciences tech giant plans to spin out its Nutrition […]
MiniMed completes split from Medtronic
MiniMed (Nasdaq: MMED) is celebrating its first day as an independent diabetes tech company, with the full completion of its spinoff from the Medtronic mothership. This week Medtronic reported the final results of its exchange offer for MiniMed stock, where it divested all of its remaining equity stake in the company through the swapping of […]
Heart implant maker BioVentrix withdraws plans for Nasdaq IPO
BioVentrix has withdrawn its plans to go public, after pitching a Nasdaq IPO earlier this year that aimed to raise about $17 million. In a filing with the SEC, the Massachusetts-based company said the terms of the offering were never set and no securities were sold, following the submission of its S-1 in February. It […]
Johnson & Johnson MedTech sets mid-2027 target for ortho spinoff, as Q3 device sales disappoint
Johnson & Johnson MedTech (NYSE: JNJ) has officially set a mid-2027 target for its DePuy Synthes orthopedics unit spinoff, while reporting broader medical device sales coming in below analyst expectations for the third quarter. The company’s leadership described facing international headwinds in medtech, including volume-based procurement changes in China and the ongoing conflicts in the […]
Integra LifeSciences says Cincinnati plant flooding will cost millions
Following heavy rains and flash flooding in the Cincinnati area this past July, Integra LifeSciences (NASDAQ: IART) said it expects the water damage at one of its manufacturing facilities will lead to millions lost in revenue, with a full recovery stretching into next year. The plant, located on the city’s East Side near creeks that […]
Smart ring maker Oura postpones anticipated IPO
The smart ring maker Oura is putting off its Nasdaq IPO, citing market uncertainty shortly after outlining plans to raise as much as $2.2 billion on a $15 billion valuation. In its announcement of the delay, the company said it is still growing and profitable, with 5.7 million users, and it plans to post 90% […]
Cooper Companies continues to see activist pressure to sell divisions, replace CEO
Activist investor Jana Partners continues to push for changes at the Cooper Companies (NASDAQ: COO). The firm reiterated its calls for the medtech to sell off its various divisions in a letter to the board of directors late last week, and now it’s lobbying for the replacement of its CEO. Cooper Companies representatives couldn’t be […]
Citi downgrades Boston Scientific as cyberattack recovery compounds competitive pressure
Analysts at Citigroup bowed to the uncertainty surrounding Boston Scientific’s (NYSE:BSX) immediate financial future, delivering a downgrade to its stock rating as headwinds in its cardiac business are complicated by its recovery from a major cyberattack last month. Citi’s researchers have lowered their estimates for the company eight times so far this year, most recently […]
